| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cassiaside targets BACE1 (beta-site amyloid precursor protein cleaving enzyme 1). It exhibits mixed inhibition of BACE1 with an IC50 of 4.45 μM and a Ki of 9.85 μM. By inhibiting BACE1, Cassiaside reduces the production of amyloid-beta peptides, which are involved in Alzheimer's disease pathology. The compound's mechanism involves binding to BACE1 and preventing it from cleaving amyloid precursor protein. Cassiaside also exhibits antioxidant, hepatoprotective, and anti-inflammatory effects.
|
|---|---|
| ln Vitro |
In vitro, Cassiaside exhibits mixed inhibition of BACE1 with an IC50 of 4.45 μM and a Ki of 9.85 μM. The compound shows antioxidant, hepatoprotective, and anti-inflammatory effects. Standard in vitro assays include BACE1 enzyme activity assays using fluorogenic substrates, antioxidant assays (e.g., DPPH radical scavenging), and anti-inflammatory assays measuring cytokine production in immune cells. The compound's potential anti-Alzheimer's disease activity is assessed through its BACE1 inhibitory activity.
|
| ln Vivo |
In vivo, Cassiaside has shown promise in protecting against oxidative liver injury and metabolic disorders. It possesses mild laxative properties. The compound exhibits strong antioxidant and hepatoprotective effects. However, comprehensive in vivo efficacy data for Alzheimer's disease are limited. The compound is used in research to study its potential therapeutic applications in liver protection, inflammation, and Alzheimer's disease. Further in vivo studies are needed to fully characterize its efficacy.
|
| Enzyme Assay |
For non-cell-based receptor binding assays, Cassiaside can be evaluated using purified BACE1 enzyme. Enzyme activity assays are performed using a fluorogenic substrate that is cleaved by BACE1. Increasing concentrations of the test compound are added, and the rate of substrate cleavage is measured by fluorescence. IC50 values are calculated from the inhibition curves. The mixed inhibition mechanism is confirmed by performing enzyme kinetics at various substrate concentrations and analyzing Lineweaver-Burk plots. Ki values are calculated from the kinetic data.
|
| Cell Assay |
For in vitro cellular assays, cells expressing amyloid precursor protein (APP) are cultured in appropriate media. Cells are treated with various concentrations of Cassiaside, and Aβ production in the cell culture supernatant is measured using ELISA or immunoassay. For antioxidant assays, cells are treated with oxidative stressors in the presence or absence of the compound, and oxidative stress markers are measured. For anti-inflammatory assays, immune cells are stimulated with LPS or other inflammatory stimuli, and cytokine production is measured.
|
| Animal Protocol |
For in vivo animal studies, Cassiaside is typically administered to rodents via oral gavage. In models of oxidative liver injury, liver enzyme levels (ALT, AST) and oxidative stress markers are measured following compound administration. In inflammation models, inflammatory markers and tissue damage are assessed. In Alzheimer's disease models, brain Aβ levels and cognitive function may be evaluated. Dosing regimens vary depending on the specific model. Blood and tissue samples may be collected for pharmacokinetic analysis.
|
| ADME/Pharmacokinetics |
Cassiaside has a molecular weight of 420.37 and a molecular formula of C20H20O10. It is a phenolic glycoside with an anthraquinone or naphthopyrone core linked to a sugar moiety. The compound is soluble in appropriate solvents for research use. It is supplied in high purity (≥95%). Cassiaside is isolated from Cassia species, particularly Cassia tora and Cassia obtusifolia. It should be stored according to the manufacturer's recommendations. It is for research use only.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Cassiaside has not been extensively reported. As a natural product from Cassia species, it is expected to have a favorable safety profile. The compound exhibits strong antioxidant and hepatoprotective effects, suggesting it may have protective rather than toxic properties. It possesses mild laxative properties. The compound is for research use only and not for human consumption. Standard toxicological evaluation would include acute and repeated-dose toxicity studies.
|
| References | |
| Additional Infomation |
Cassiaside is a glycoside and a benzochrome ketone. It has been reported that cassia glycoside exists in Cassia obtusifolia and Cassia tora, and relevant data are available for reference.
Cassiaside is a phenolic glycoside isolated from Cassia species, particularly Cassia tora and Cassia obtusifolia. It exhibits mixed inhibition of BACE1 with an IC50 of 4.45 μM and a Ki of 9.85 μM. The compound possesses potential anti-Alzheimer's disease activity. It also exhibits strong antioxidant, hepatoprotective, and anti-inflammatory effects. Cassiaside is used in research to study its potential therapeutic applications in liver protection, inflammation, and Alzheimer's disease. |
| Molecular Formula |
C20H20O9
|
|---|---|
| Molecular Weight |
404.367406845093
|
| Exact Mass |
404.11
|
| CAS # |
13709-03-0
|
| PubChem CID |
164146
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
1.2
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
29
|
| Complexity |
652
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1[C@H]([C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O)OC1=CC=CC2=CC3=C(C(C=C(C)O3)=O)C(=C12)O
|
| InChi Key |
SBVZTBIAKFTNIJ-CZNQJBLBSA-N
|
| InChi Code |
InChI=1S/C20H20O9/c1-8-5-10(22)15-12(27-8)6-9-3-2-4-11(14(9)17(15)24)28-20-19(26)18(25)16(23)13(7-21)29-20/h2-6,13,16,18-21,23-26H,7H2,1H3/t13-,16-,18+,19-,20-/m1/s1
|
| Chemical Name |
5-hydroxy-2-methyl-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzo[g]chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4730 mL | 12.3649 mL | 24.7298 mL | |
| 5 mM | 0.4946 mL | 2.4730 mL | 4.9460 mL | |
| 10 mM | 0.2473 mL | 1.2365 mL | 2.4730 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
